Funding · Healthcare & Life Sciences

Graph AI raises $13.3M for US and Europe expansion

By Startup Enthusiast · 10 September 2026

What they do

Graph AI builds software to automate pharmacovigilance and patient safety operations for pharma companies

The company raised $13.3 million led by Insight Partners to expand in the US and Europe

This funding accelerates product development and aligns with new global AI regulations for healthcare

Graph AI has secured $13.3 million in Series A funding.
Insight Partners led the investment round for the Indian startup.
Bessemer Venture Partners, an existing investor, also participated in this round.
The CEO is Raghav Parvataraju, who leads the company's strategic direction.
The team includes veterans from Google, Wipro, Infosys, LTI, and ServiceNow.
Company plans to use funds to expand operations in the US and Europe.
Graph AI will accelerate its product development cycle using the new capital.
The company aims to serve pharma and biotech clients in North America and other markets.

The raise follows a $3 million seed round led by Bessemer in October 2025.
Regulatory frameworks like the FDA AI framework and EU AI Act drive demand.
The CIOMS Working Group XIV report highlights the need for standardized AI tools.
Pharma companies face increasing pressure to ensure patient safety through rigorous monitoring.
Automation reduces manual errors in handling adverse event reports significantly.

Graph AI offers a Graph Safety platform for automated drug safety monitoring.
It automates pharmacovigilance and patient safety operations for pharmaceutical firms.
The tech uses AI combined with deterministic controls and validation layers.
End-to-end audit trails ensure compliance and transparency in safety reporting.
The Intake module captures and triages adverse events from various sources.
The Nucleus module serves as a safety database for case processing.
The Report module launches in September 2026 for aggregate safety reporting.
A Signal module is in development to identify emerging safety patterns.
Case processing time drops from over 3 hours to under 10 minutes.
Operating costs for clients can be reduced by up to 66%.

Insight Partners (lead) — Led the Series A round.
Bessemer Venture Partners (existing) — Participated in the round and previously led the seed round.

Product: Proprietary Graph Safety platform automating adverse drug event monitoring and regulatory submissions
Customers: Pharmaceutical and biotech companies managing drug safety and regulatory compliance
How it makes money: B2B SaaS for pharma and biotech automation
What sets it apart: AI-native platform replacing manual pharmacovigilance processes with automated adverse event detection and reporting